AU2022431253A1 - Serpin peptides and methods of using the same - Google Patents
Serpin peptides and methods of using the same Download PDFInfo
- Publication number
- AU2022431253A1 AU2022431253A1 AU2022431253A AU2022431253A AU2022431253A1 AU 2022431253 A1 AU2022431253 A1 AU 2022431253A1 AU 2022431253 A AU2022431253 A AU 2022431253A AU 2022431253 A AU2022431253 A AU 2022431253A AU 2022431253 A1 AU2022431253 A1 AU 2022431253A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- peptide
- serpin
- disease
- serpin peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263266444P | 2022-01-05 | 2022-01-05 | |
| US63/266,444 | 2022-01-05 | ||
| PCT/US2022/082669 WO2023133078A2 (en) | 2022-01-05 | 2022-12-30 | Serpin peptides and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022431253A1 true AU2022431253A1 (en) | 2024-07-25 |
Family
ID=87074167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022431253A Pending AU2022431253A1 (en) | 2022-01-05 | 2022-12-30 | Serpin peptides and methods of using the same |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20250161419A1 (enExample) |
| EP (1) | EP4460322A4 (enExample) |
| JP (1) | JP2025503607A (enExample) |
| CN (1) | CN118804758A (enExample) |
| AU (1) | AU2022431253A1 (enExample) |
| CA (1) | CA3247129A1 (enExample) |
| IL (1) | IL314135A (enExample) |
| WO (1) | WO2023133078A2 (enExample) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113429455B (zh) * | 2015-08-28 | 2024-11-22 | 赛品制药有限责任公司 | 用于疾病治疗的方法 |
| US10821094B2 (en) * | 2016-01-13 | 2020-11-03 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
| WO2019199634A1 (en) * | 2018-04-09 | 2019-10-17 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
| US20240342293A1 (en) * | 2019-10-10 | 2024-10-17 | Yale University | Engineered antibodies as molecular degraders through cellular receptors |
| EP4054713A4 (en) * | 2019-11-04 | 2024-02-07 | Azitra, Inc. | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING SKIN DISEASES AND DISORDERS USING LEKTI |
| US11779630B2 (en) * | 2020-07-06 | 2023-10-10 | Serpin Pharma, Llc | Peptides and methods of using the same |
| EP4294392A4 (en) * | 2021-02-22 | 2025-06-25 | Yale University, Inc. | TARGETED BIFUNCTIONAL DEGRADING AGENTS AND METHODS OF USE THEREOF |
-
2022
- 2022-12-30 AU AU2022431253A patent/AU2022431253A1/en active Pending
- 2022-12-30 WO PCT/US2022/082669 patent/WO2023133078A2/en not_active Ceased
- 2022-12-30 US US18/726,945 patent/US20250161419A1/en active Pending
- 2022-12-30 JP JP2024540848A patent/JP2025503607A/ja active Pending
- 2022-12-30 CA CA3247129A patent/CA3247129A1/en active Pending
- 2022-12-30 EP EP22919262.0A patent/EP4460322A4/en active Pending
- 2022-12-30 CN CN202280092284.4A patent/CN118804758A/zh active Pending
- 2022-12-30 IL IL314135A patent/IL314135A/en unknown
-
2023
- 2023-07-13 US US18/148,942 patent/US20230406906A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4460322A4 (en) | 2026-02-25 |
| IL314135A (en) | 2024-09-01 |
| US20250161419A1 (en) | 2025-05-22 |
| WO2023133078A3 (en) | 2023-08-17 |
| WO2023133078A2 (en) | 2023-07-13 |
| EP4460322A2 (en) | 2024-11-13 |
| US20230406906A1 (en) | 2023-12-21 |
| JP2025503607A (ja) | 2025-02-04 |
| CN118804758A (zh) | 2024-10-18 |
| CA3247129A1 (en) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Oxymatrine attenuates bleomycin-induced pulmonary fibrosis in mice via the inhibition of inducible nitric oxide synthase expression and the TGF-β/Smad signaling pathway | |
| Wu et al. | Recombinant adiponectin peptide promotes neuronal survival after intracerebral haemorrhage by suppressing mitochondrial and ATF4‐CHOP apoptosis pathways in diabetic mice via Smad3 signalling inhibition | |
| Chen et al. | Carbon monoxide ameliorates acetaminophen‐induced liver injury by increasing hepatic HO‐1 and Parkin expression | |
| US11779630B2 (en) | Peptides and methods of using the same | |
| US20210008177A1 (en) | Elapidae neurotoxin enhances opioid analgesic effect and inhibits opioid induced hyperalgesia and tolerance | |
| Tamai et al. | Caveolae in mesangial cells and caveolin expression in mesangial proliferative glomerulonephritis | |
| Yang et al. | Resolvin D2 activates anti-inflammatory microglia via restoring autophagy flux and alleviate neuropathic pain following spinal cord injury in rats | |
| Chen et al. | Asiatic acid alleviates cisplatin-induced renal fibrosis in tumor-bearing mice by improving the TFEB-mediated autophagy-lysosome pathway | |
| Yang et al. | Effect of Acer tegmentosum bark on atopic dermatitis-like skin lesions in NC/Nga mice | |
| Lin et al. | Peroxisome proliferator-activator receptor γ and psoriasis, molecular and cellular biochemistry | |
| Xu et al. | The NLRP3 activation in infiltrating macrophages contributes to corneal fibrosis by inducing TGF-β1 expression in the corneal epithelium | |
| EP3257520B1 (en) | Ostreolysin for use in the treatment of steatohepatitis | |
| US20190216901A1 (en) | Acth prophylactic treatment of renal disorders | |
| Cao et al. | Intracellular and extracellular Cyclophilin a promote cardiac fibrosis through TGF-β signaling in response to angiotensin Ⅱ | |
| CA3129405A1 (en) | Growth hormone-releasing hormone antagonists and uses thereof | |
| US20250161419A1 (en) | Serpin peptides and methods of using the same | |
| EP3967705A1 (en) | Rvg derived peptides | |
| HK40118659A (zh) | Serpin肽及其使用方法 | |
| Wanas et al. | The potential therapeutic role of Lisinopril in augmenting the striatal neuroplasticity via the striatal ACE2/Ang1-7/MAS receptor axis in 3-nitropropionic acid-induced Huntington’s disease in rats: shifting paradigms in Huntington’s disease treatment | |
| KR20230034167A (ko) | Kai1 폴리펩타이드를 포함하는 간 섬유화 억제용 약학 조성물 및 이의 용도 | |
| Lee et al. | Protective Effect of Delta-Like 1 Homolog against muscular atrophy in a mouse model | |
| HK40121727A (zh) | Serpin肽衍生物及其使用方法 | |
| WO2016011133A1 (en) | A peptide therapy to counteract insulin resistance and type 2 diabetes | |
| AU2023260921A1 (en) | Serpin peptide derivatives and methods of using the same | |
| Chen et al. | Etomidate protects against homocysteine-induced blood-brain barrier disruption via upregulation of Krüppel-like factor 2 |